Ubs Asset Management Americas Inc Rhythm Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 225,373 shares of RYTM stock, worth $12.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225,373
Previous 236,431
4.68%
Holding current value
$12.7 Million
Previous $9.71 Million
21.63%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding RYTM
# of Institutions
192Shares Held
67.3MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$406 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$379 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$360 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$342 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$218 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.13B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...